Free tool
FAERS Monitor: Thalitone
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019574 or its brand name (Thalitone, Chlorthalidone). Reports on generic versions are filed under their own applications.
Reports
11,770
Serious
7,408
63% of reports
Hospitalization
3,768
Death reported
704
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue919
- nausea758
- drug ineffective756
- diarrhoea700
- dizziness598
- pain569
- off label use564
- headache557
- dyspnoea536
- acute kidney injury476
- chronic kidney disease461
- arthralgia457
- asthenia447
- hypertension410
- blood pressure increased399
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 40 |
| 2006 | 61 |
| 2007 | 44 |
| 2008 | 68 |
| 2009 | 88 |
| 2010 | 128 |
| 2011 | 171 |
| 2012 | 215 |
| 2013 | 224 |
| 2014 | 344 |
| 2015 | 535 |
| 2016 | 671 |
| 2017 | 615 |
| 2018 | 785 |
| 2019 | 953 |
| 2020 | 887 |
| 2021 | 954 |
| 2022 | 1,064 |
| 2023 | 1,009 |
| 2024 | 1,056 |
| 2025 | 1,135 |
| 2026 | 691 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,389 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 461 | 10.9 | 10.0 | 4,126 |
| acute kidney injurySignal | 476 | 5.6 | 5.1 | 1,789 |
| blood pressure increasedSignal | 399 | 4.7 | 4.2 | 1,154 |
| hypertensionSignal | 410 | 3.5 | 3.1 | 722 |
| dizzinessSignal | 598 | 2.1 | 2.0 | 372 |
| astheniaSignal | 447 | 2.1 | 1.9 | 270 |
| fatigueSignal | 919 | 2.1 | 2.0 | 556 |
| arthralgia | 457 | 2.0 | 1.8 | 220 |
| diarrhoea | 700 | 1.9 | 1.8 | 327 |
| nausea | 758 | 1.7 | 1.6 | 232 |
| dyspnoea | 536 | 1.7 | 1.6 | 155 |
| pain | 569 | 1.7 | 1.5 | 151 |
| headache | 557 | 1.6 | 1.5 | 124 |
| off label use | 564 | 1.2 | 1.1 | 12 |
| drug ineffective | 756 | 1.0 | 1.0 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.